Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-10, Stock:NVS, The news for the past five days is as follows:
2019-06-03: NEWS1: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS2: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS3: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS4: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS5: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS6: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS7: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS8: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS9: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS10: Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials.
2019-06-04: NEWS1: It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy.NEWS2: It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy.NEWS3: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.NEWS4: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.NEWS5: Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®.NEWS6: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.
2019-06-05: NEWS1: Continued Smart M&A Moves Will Help Canopy Stock Break Out.NEWS2: Continued Smart M&A Moves Will Help Canopy Stock Break Out.NEWS3: Continued Smart M&A Moves Will Help Canopy Stock Break Out.
2019-06-06: NEWS1: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS2: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS3: Alnylam Completes Rolling NDA Submission to FDA for Givosiran.NEWS4: Alnylam Completes Rolling NDA Submission to FDA for Givosiran.NEWS5: Alnylam Completes Rolling NDA Submission to FDA for Givosiran.NEWS6: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS7: Was ASCO Quieter for Big Drug/Biotech Stocks This Year?.NEWS8: Was ASCO Quieter for Big Drug/Biotech Stocks This Year?.NEWS9: Was ASCO Quieter for Big Drug/Biotech Stocks This Year?.NEWS10: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering.
2019-06-07: NEWS1: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS2: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS3: Celgene's Filing for Ozanimod Accepted for Review in US/EU.NEWS4: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS5: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS6: Sanofi's Leadership Transition: What You Need To Know.NEWS7: New Sanofi CEO 2019: 8 Things to Know About Paul Hudson.NEWS8: Here’s What Hedge Funds Think About Novartis AG  (NVS).NEWS9: Sanofi Taps Novartis Executive as CEO in Race for New Drugs.NEWS10: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS11: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS12: Novartis Appoints New Pharma Unit Head, Gives Other Updates.NEWS13: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix.NEWS14: Sanofi appoints top Novartis executive as new chief.NEWS15: Sanofi says Paul Hudson to succeed Olivier Brandicourt as chief.NEWS16: StockBeat: Markets Rise as Miserable German Data Boost QE Hopes.

Answer: Rise